The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
DY Suharya, ADI Regional director for Asia Pacific, will lead on a Values 20 (V20) work stream in preparation for the G20 summit, taking place on 15-16 November 2022.
If you are living with dementia, a carer, clinician, formal (paid) health or long-term care practitioner, we need to hear about your experience of post-diagnosis for the World Alzheimer Report 2022.
ADI is pleased to announce the formalisation of a long-standing collaboration with World Wide-FINGERS (WW-FINGERS) by joining in partnership to reduce the risk of dementia worldwide.
ADI delivered important statements to the World Health Organization (WHO) and Member States on the importance of considering those living with dementia and carers in pandemic responses, humanitarian crises, as well as a new neurological global action plan.
The Centers for Medicare & Medicaid Services (CMS) in the US confirms requirement for clinical trials to access Aduhelm but broadens which trials are eligible.
The study by Institute for Health Metrics and Evaluation (IHME) published in The Lancet predicts 153 million people will be living with Alzheimer’s disease by 2050.
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.
As 2021 comes to an end, ADI CEO Paola Barbarino reflects on the work of ADI in 2021 and what we are looking towards to in 2022.